RE:RE:RE:wow, what a great day.... "In accordance with FDA guidelines to industry, the patients who have achieved a PR are being further assessed via CT scan and biopsy of the prostatic urethra to determine if upper tract Urothelial Cell Carcinoma (“UCC”) or prostatic urethra UCC can be detected to allow these patients to be re-categorized as CR."
Hope we get clarification on those 2 patients and pray that they come out CR.
enriquesuave wrote:
For the next report, it would be good to see the 3 months data for all pending patients and partial responders final confirmation as well as 9 months data ( 3 months after 2nd treatment). We were just given data after one single treatment which is 3 and 6 months. After 2nd treatment I hope we see all those CR maintaining CR status at 9 months and possibly a few more others become CR.
enriquesuave wrote: I don't know what the market expected, but we knew that we would only get the same data as last Q report plus patients 13-15. So far the treatment is showing at least 6 months durability just when patients will get treated a second time with an optimized treatment. As for 13-15 so far 2 out of 3 are CR. Not bad. Just need more data, and even if we just get good news from those pending and maybe clarify the partial responders, then market will have a better idea of efficacy potential. We are still negatively affected by the under treatment of the first set of 12 and not enough new data. IMO